Jul 18, 2025
Newsroom
Material Information - The Company Announces Filing of New Drug Submission of BESREMi (Ropeginterferon alfa-2b) for PV in Canada
Learn MoreJul 16, 2025
Newsroom
Material Information - The China NMPA has Accepted the Marketing Authorization Application of Ropeginterferon alfa-2b for ET
Learn MoreJun 30, 2025
Newsroom
Material Information - The Company Announces Submission of Marketing Authorization Application of Ropeginterferon alfa-2b (P1101) for ET in China
Learn MoreJun 18, 2025
Newsroom
Material Information - Argentina ANMAT has Approved the Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2b) for PV
Learn MoreJun 12, 2025
Newsroom
Material Information - Update on the Company's IND Application of Phase I Clinical Trial of TCRT-ESO-A2-TW in Patients with Advanced Solid Tumors
Learn MoreJun 4, 2025
Newsroom
PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms
Learn MoreMay 24, 2025
Newsroom
Material Information - Announcement of the Topline Results from the Phase I Clinical Trial of PharmaEssentia's Long-acting GCSF, P2203
Learn MoreMay 21, 2025
Newsroom
PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting
Learn MoreMay 19, 2025
Newsroom
Material Information - The Board Approved to Set Aside the Partial Final Award on the ICC Arbitration Against AOP, and to Request Suspension of the Second Phase of Proceedings
Learn MoreApr 30, 2025
Newsroom
Material Information - Update on the Company's IND Application of Phase I Clinical Trial of TCRT-ESO-A2-TW in Patients with Advanced Solid Tumors
Learn More